IVIM Technology, Inc (460470) Fair Value & Analysis
Healthcare · KR · Market cap 53.2B KRW
Fair value as of: Jun 24, 2026
Analysis
IVIM Technology, Inc (460470) currently trades at 3,250 KRW, while our model-based Fair Value estimate is 5,492 KRW — implying the stock looks roughly 69.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
IVIM Technology, Inc. develops intravital microscopy (IVM) platform. Its products include IVM-C3, a system for simultaneously observing various multi-cellular behaviors in small live animal models; IVM-M3, a system for users who need to conduct deeper-tissue imaging using less-scattering NIR wavelength; IVM-CMS3 for intravital functional imaging; IVM-CM3 that provides three-dimensional imaging of living cells near the skin or deep into the tumor in small animals; IVM-MS3 for in vivo imaging; and IVM-customized products. The company also provides preclinical contract research organization services. Its products are used in live cell intravital imaging, repetitive intravital imaging, in vivo drug efficacy monitoring, in vivo drug delivery monitoring, and ex vivo imaging applications. The company was founded in 2017 and is based in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is IVIM Technology, Inc (460470) undervalued?
What is the fair value of 460470?
What is the quality score of 460470?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.